secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001493152-24-043915
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate posts narrower Q3 loss, cash jumps to $10M as it advances ADHD drug toward mid-2025 NDA
--------------------------------------------------------------------------------

- Net loss $3.2M vs $6.0M in Q3 2023; R&D expenses fell $2.5M to $1.4M.
- Cash and equivalents $10M at Sep 30, 2024, up from $52K at Dec 31, 2023.
- Working capital $9.8M, an increase of $19.5M from negative $9.6M at year-end 2023.
- Raised ~$12.5M in Q3; cash runway extended into Q3 2025.
- Commenced final FDA food-effect study for CTx-1301; data readout by end of 2024; NDA submission targeted mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000149315224043915/0001493152-24-043915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000149315224043915/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-043915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer